PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.01%
Positive revenue growth while ACB.TO is negative. John Neff might see a notable competitive edge here.
-129.16%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-2648.08%
Negative EBIT growth while ACB.TO is at 334.93%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-2648.08%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-1840.05%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-1840.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-1840.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.63%
Slight or no buybacks while ACB.TO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.63%
Diluted share reduction more than 1.5x ACB.TO's 13.59%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-163.79%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-178.99%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
297.40%
Positive 5Y CAGR while ACB.TO is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
-52.47%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-297.77%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-3403.96%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
83.35%
3Y OCF/share CAGR similar to ACB.TO's 87.93%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
-51280.40%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-2688.92%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-9959.44%
Negative 3Y CAGR while ACB.TO is 97.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
6257.60%
10Y equity/share CAGR above 1.5x ACB.TO's 151.01%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
29.59%
Positive 5Y equity/share CAGR while ACB.TO is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-12.97%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.67%
Firm’s AR is declining while ACB.TO shows 4.11%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-15.83%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-20.07%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-24.48%
We have a declining book value while ACB.TO shows 0.58%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.85%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
3.64%
R&D dropping or stable vs. ACB.TO's 60.34%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-11.81%
We cut SG&A while ACB.TO invests at 27.63%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.